The Offeror has announced through a press release on 13 March 2024 the outcome of the Offer. Following the Offer, the Offeror controls a total of 41,498,279 shares in Biokraft, corresponding to approximately 95.2 per cent of the total number of shares and votes in Biokraft. To enable those shareholders who have not yet accepted the Offer to transfer their shares to the Offeror, the Offeror has extended the acceptance period of the Offer until 27 March 2024 at 3.00 p.m.

The Offeror has requested compulsory redemption regarding the remaining shares in the Company.

In the light of the above, the Board of Directors of Biokraft has today resolved, in accordance with the Offeror's request, to apply for delisting of the Company's shares from Nasdaq First North Premier Growth Market. The last day of trading in Biokraft's shares on Nasdaq First North Premier Growth Market will be announced as soon as the Company has received confirmation thereof from Nasdaq Stockholm.

By reason of the Offer, the Board of Directors of Biokraft has also resolved to postpone the publication of the 2023 annual report. The new date for the publication of the 2023 annual report will be presented when it has been decided. 

The Board of Directors of Biokraft has also, at the request of the Offeror, resolved to convene another extraordinary general meeting to be held on 15 April 2024 to change the Board of Directors. The notice to the extraordinary general meeting will be announced through a separate press release.

This information was submitted, through the care of the below contact person, for publication on 22 March 2024 at 18:50 CET.